Argo Biopharmaceutical Co., Ltd confirmed that the first patient has been dosed in a global Phase 2b trial of BW-20829 (also called DII235), a small interfering RNA (siRNA) therapeutic licensed to Novartis. The trial will assess BW-20829 in adult patients with elevated lipoprotein(a), or Lp(a), and existing atherosclerotic cardiovascular disease (ASCVD). The study represents a significant mid-stage advancement for Argo Biopharma’s RADS platform, which enables targeted hepatic RNA interference. The development milestone also triggers payments to Argo under its license agreement with Novartis and marks the company’s sixth candidate to reach global Phase 2 trials.

Lipoprotein(a) emerges as the next big lipid target as statins reach efficacy ceilings

Lipoprotein(a) has long been considered a strong independent risk factor for cardiovascular disease, but it has not yet been addressed by mainstream therapies. Unlike LDL cholesterol, which can be managed by statins, ezetimibe, or PCSK9 inhibitors, Lp(a) levels are primarily determined by genetics and are only modestly impacted by existing treatments. Clinicians have increasingly observed that even patients with controlled LDL levels can experience recurrent cardiovascular events if their Lp(a) remains elevated.

The growing recognition of this residual risk has catalyzed the search for therapies that specifically reduce Lp(a). While awareness has increased among cardiologists, few interventional options have reached clinical utility. BW-20829 enters a relatively uncontested therapeutic space at a time when major pharmaceutical players are ramping efforts to build new cardiometabolic franchises beyond LDL reduction. In this context, Novartis’ backing signals confidence that Lp(a)-targeted RNAi could define the next frontier in cardiovascular risk management.

BW-20829’s mechanism leverages the liver-specific delivery strengths of siRNA

BW-20829 is based on Argo Biopharma’s RADS platform, a proprietary siRNA technology designed for durable, tissue-specific gene silencing. The drug targets hepatic synthesis of apolipoprotein(a), the key component of Lp(a), making the liver a strategic delivery target. The platform allows precise inhibition of the LPA gene, offering the possibility of sustained suppression with infrequent dosing.

This approach is structurally differentiated from prior generation RNAi therapies that were challenged by short half-lives, systemic delivery hurdles, and off-target effects. With RADS, Argo Biopharma emphasizes long-acting activity, reduced injection burden, and improved tolerability—all critical for chronic cardiovascular use cases. These technical parameters are increasingly non-negotiable for payers, regulators, and providers assessing scalability for widespread ASCVD risk reduction.

Novartis’ Phase 2b initiation could reposition siRNA as a mainstream cardiovascular modality

Novartis’ decision to lead global Phase 2b development of BW-20829 signals a strategic intent to expand beyond its current siRNA flagship, inclisiran (Leqvio), which targets PCSK9 to reduce LDL cholesterol. While inclisiran is approved in multiple geographies, it does not substantially lower Lp(a), creating room for a complementary or next-in-line asset.

By activating the BW-20829 program, Novartis appears to be investing in a second siRNA franchise aimed squarely at the residual risk market segment—those ASCVD patients whose events persist despite aggressive LDL control. This cohort has increasingly been identified in sub-analyses of large CVOTs (cardiovascular outcomes trials), which have repeatedly demonstrated that Lp(a) levels predict MACE independently of LDL.

The trial’s start, therefore, is more than an operational milestone. It underscores a growing institutional belief that RNAi could become a foundational pillar in the cardiologist’s toolbox, potentially occupying a role similar to statins two decades ago—except for a genetically stratified patient population.

Competition is rising but BW-20829 may have first-mover advantage in durable Lp(a) suppression

The RNAi landscape for Lp(a) reduction is quickly gaining traction. Silence Therapeutics has SLN360 in development, and Alnylam Pharmaceuticals has previously hinted at internal preclinical programs. However, BW-20829’s advancement into Phase 2b makes it one of the furthest along in clinical development. The question is whether this temporal lead can be maintained into Phase 3 and commercial execution.

Unlike gene editing approaches, which are also being explored for lipid regulation, RNAi therapies can be dosed repeatably and modulated over time, offering clinical reversibility. This pharmacologic flexibility may make siRNAs more suitable for wide patient adoption, particularly where lifetime exposure and long-term tolerability are required.

Investors and industry observers will be watching closely to see if BW-20829 delivers not just effective Lp(a) reduction, but also consistent pharmacodynamic response, a clean safety profile, and practical dosing intervals. If those are achieved, Argo Biopharma could find itself in possession of a platform-defining asset with both competitive insulation and licensing leverage.

Study design will shape interpretation, especially in absence of hard cardiovascular endpoints

The current Phase 2b trial (NCT07235046) is designed primarily to evaluate safety, tolerability, and efficacy in reducing plasma Lp(a) levels over a defined treatment period. However, regulatory watchers note that such biomarker endpoints—while important—are still not universally accepted as surrogates for clinical outcomes. To secure regulatory approvals or label expansions, eventual Phase 3 programs will likely need to incorporate MACE as a primary or co-primary endpoint.

This requirement places added pressure on Argo Biopharma and Novartis to ensure that BW-20829’s Lp(a) reductions are both substantial and clinically interpretable. For now, Phase 2b serves as a mechanistic proof point, but not a clinical validation. The magnitude of Lp(a) lowering needed to reduce events remains an area of active debate, and even a 70–90% reduction may need outcome trials to prove relevance.

For BW-20829 to reach market, it will need to satisfy regulators that durable Lp(a) suppression materially alters ASCVD trajectories—a challenge that hinges on both biomarker strength and future trial architecture.

The licensing structure enables Argo Biopharma to preserve innovation while de-risking development

Under the terms of the agreement, Argo Biopharma continues to focus on platform innovation and early-stage discovery, while Novartis takes on the responsibility of later-stage development and commercialization. This bifurcated model, common in RNAi partnerships, allows Argo to build enterprise value through pipeline breadth without assuming capital-intensive late-phase trial risk.

This milestone also triggers additional payments from Novartis to Argo, which will be reinvested into advancing the company’s hepatic and extra-hepatic siRNA pipeline. Analysts following the sector suggest that such licensing deals not only validate the platform but also offer flexibility in portfolio construction. Argo can now prioritize other preclinical candidates, confident that at least one of its assets is gaining global development traction.

Furthermore, this strategy shields Argo from dilution or overextension—a risk that has historically derailed promising RNAi firms during late-phase transitions.

What BW-20829’s success or failure would mean for the broader siRNA therapeutic class

The significance of BW-20829 goes beyond Argo Biopharma. Success here would represent a powerful validation of siRNA’s versatility and scalability, positioning RNAi as a modality that can tackle prevalent, chronic conditions like ASCVD—not just rare diseases. Conversely, any late-stage failure due to safety, insufficient efficacy, or biomarker irrelevance would set back RNAi’s ambitions in cardiology by several years.

In that sense, BW-20829 is not just a molecule—it’s a bellwether. If it delivers, platform companies working on extra-hepatic delivery, gene targets in CNS or pulmonary disorders, and combination therapies could gain institutional credibility and attract faster partnering interest. If it stalls, it may reinforce the notion that RNAi, while potent, is best kept within tightly defined rare or hepatic indications.

Either way, Argo Biopharma has positioned itself at a critical intersection of scientific promise and therapeutic need—one where execution, not concept, will determine impact.

  Argo Biopharma, ASCVD, BW-20829, cardiovascular trials, DII235, lipoprotein(a), Novartis, RADS platform, RNAi therapy, siRNA